Evidence map›Paper›PMID 41899534›Full record

ArticleCancers2026

Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with Glofitamab.

Maeva Ullmann, Katja Seipel, Henning Nilius, Martina Bertschinger, Vera Rentsch, Ulrike Bacher, Thomas Pabst

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maeva UllmannDepartment of Medical Oncology, Inselspital, University of Bern, 3010 Bern, Switzerland.
Katja SeipelDepartment of Medical Oncology, Inselspital, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0003-3128-1573
Henning NiliusDepartment of Clinical Chemistry, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.ORCID 0000-0002-1323-3116
Martina BertschingerDepartment of Medical Oncology, Inselspital, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0003-1736-812X
Vera RentschDepartment of Medical Oncology, Inselspital, University of Bern, 3010 Bern, Switzerland.
Ulrike BacherDepartment for Biomedical Research (DBMR), University of Bern, 3008 Bern, Switzerland.ORCID 0000-0001-8771-947X
Thomas PabstDepartment of Medical Oncology, Inselspital, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0002-6055-5257

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlofitamab is a bispecific antibody engaging CD3 on T-cells and CD20 on B-cells. Glofitamab is approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma (R/R DLBCL). Lymphocyte-activation gene 3 (LAG3) and T-lymphocyte-associated protein 4 (CTLA4) are immune checkpoint receptors with inhibitory effects on T-cell activity. There are several common germline variants of both receptor genes.

methodsHere, we evaluate clinical outcomes in R/R DLBCL patients treated with glofitamab according to the single-nucleotide polymorphisms

resultsWhile there was no apparent association of

conclusions

Indexed as

bispecific antibody (BsAb)bispecific T-cell engager (BiTE)diffuse large B-cell lymphoma (DLBCL)glofitamablymphocyte-activation gene 3 (LAG3)single nucleotide polymorphism (SNP)T-lymphocyte-associated protein 4 (CTLA4)

Identifiers

PMID41899534
PMCPMC13024461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.